At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 507 enrolled
Drug / intervention
Brimonidine Tartrate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Pediatric, Adult, and Geriatric Subjects
In Brief
A Phase 3 clinical trial evaluating Brimonidine Tartrate, Vehicle, and 2 other interventions for Hyperemia. Completed, enrolled 507 participants across 4 sites.
Detailed Summary
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
Study Details
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartFeb 2014
Primary CompletionApr 2014
Study CompletionJun 2014
TodayJul 2026
First PostedOct 9, 2013
Enrollment StartFeb 22, 2014
Primary CompletionApr 23, 2014
Study CompletionJun 23, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.7 years ago
Interventions
Brimonidine Tartratedrug
Ophthalmic solution to be applied as directed.
Vehicledrug
Ophthalmic solution to be applied as directed.
Sodium Fluoresceindrug
For use as needed during the study for evaluating corneal damage.
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USPdrug
For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.